 |
| Apple Inc |
When we compare industry giants in terms of raw cash numbers ( including cash equivalents and short term marketable securities ), Apple was lying at No 6. but when we look at closely, it reveal Apple Inc as an unbeaten horse in a long term race.
Apple Inc has raw cash only $29 billion and above it General Electric with $127 billion, Microsoft with $50 billion,Cisco, $40 billion; Berkshire Hathaway, $38.8 billion; and Google, $36.6 billion.but once you include debt, General Electric and Berkshire is out and reduce cash numbers of Microsoft and Cisco. After all Google and Apple left in the race.
Now when you add $35.6 billion long term marketable securities in debt free Apple Inc which is almost equivalent to Google's cash numbers, it makes Apple Inc with $65 billion of cash numbers easily topping the Google Inc.
According to analyst Jon Fortt, Apple Inc is on its way to generate $100 billion in cash by the end of the next fiscal year.
And don’t stumble over the “long-term” part of the equation. According to Apple’s 10-Q, long-term has maturities one to five years. While this isn’t the normal definition of “liquid” cash, it’s still cash, especially based on the components: US Treasurys, U.S. agency securities, non-US government securities, CDs, munis and the biggest component — corporate securities.
The company doesn’t disclose further detail, but no matter how it is counted and invested, Apple’s cash is growing fast, up more than $6 billion alone in the last quarter, sequentially. Most of that growth is on the long-term side, which over the past year has roughly doubled.
Asymco recently had a piece that suggested Apple’s cash could keep operations going until 2018 if revenue streams stopped completely.
Based on the total cash, some analysts believe Apple is woefully undervalued.
But others believe that the valuation argument, at this point in the company’s cycle, is futile and somewhat meaningless. All that matters is that sales and earnings keep going higher.
Longtime Apple bull Gene Munster of Piper Jaffray recently told clients in a note: “We believe investors have grown tired of the valuation argument, given the monster numbers Apple reports only creates a higher bar for the out year growth rates. Even if the multiple remains depressed, we expect shares of AAPL to move higher driven by earnings growth.”
He added in a note to me: “The reason why most analysts don’t factor the cash into Apple’s valuation is the company has not done anything with the cash, and the theme I keep hearing is ‘don’t give them credit for the cash because we will never see it’.”
At least they haven’t yet gone out and blown it on something stupid. Restraint, especially for a company that is firing on all cylinders, is sometimes a good thing.
(Source: CNBC )
 |
| China Shengda Packaging Group Inc |
China Shengda Packaging Group Inc. (NASDAQ: CPGI) has announced that it has launched a website in English to provide on time and reliable information to the investors in the US. The message behind it was Launching a website in English helping a stock to move higher around 25%.
( PR NEWSWIRE )China Shengda Packaging Group Inc. (NASDAQ: CPGI) ("China Shengda Packaging" or the "Company"), a leading Chinese paper packaging manufacturer, today announced that it has launched a new English corporate website under the domain name of www.cnpti.com.
The new website is designed to strengthen China Shengda Packaging's communications with investors, customers and business partners, and can be accessed at http://www.cnpti.com . The website's investor relations section will provide investors with timely and reliable information in order to maintain transparency and consistency. The website provides key information on China Shengda Packaging, including corporate overview, corporate history, management team, product and operations, R&D information, corporate news, and investor information, including access to SEC filings, investor presentations, corporate profile and press releases.
"We are delighted to launch our new website and express our dedication to the investor community and customers," stated Mr.Daliang Teng, Chief Executive Officer of China Shengda Packaging. "We will use the website as a platform to provide consistent communication and create an active dialogue with our stakeholders. We view the site as part of our commitment to becoming a strong and mature U.S. publicly traded company."
 |
| Atlantis Internet Group Inc ( PINK:ATIG) |
Atlantis Internet Group ( PINK: ATIG ), company involved in online gambling has started a momentum a week ago and after a rise of more than 1000% it has shown a profit booking and gave up some of its gain, but finally stock started rising again and today it had touched all time ( 52 week ) high to $0.03. As we mentioned earlier that the story behind the move is pending congress bill to legalize online gambling, which supposed to clear my april end but there is no news as of now from Congress. Traders have started accumulating the stock in the hope that bill will be passed as Congress has a pressure to increase tax revenue of states to help budget deficits.
 |
| Cell Therapeutics Inc |
Cell Therapeutics, Inc.( NASDAQ:CTIC ) To Re-submit Pixantrone NDA In Consideration For Accelerated Approval In Accordance With Guidance From FDA's Office Of New Drugs.
Company took suggestions from different Advisory committees including FDA's office of new drugs and concluded that company might be eligible for accelerated approval of Pixantrone NDA 022481, if it provide two key matters satisfactorily resolved as mentioned below.
First, the submission of information regarding the circumstances surrounding the decision of stopping the trial early to assure that ongoing results assessment were not dictating the decision to stop.
Second, ascertainment of the soundness of the primary endpoint after an additional independent radiologic review.
If these two key matters are addressed satisfactorily, then PIX301 could be deemed successful, having achieved its primary and secondary endpoints and a re-review of safety and efficacy would be warranted.
OND denied the dispute appeal request to conclude that the efficacy of pixantrone has been demonstrated, but disagreed with the conclusion in the Complete Response Letter that PIX301 was a failed study.
Investors are waiting for final words from FDA as there is a lack of conviction in submission and resubmission from the company as concluded from the news above. Keep an eye on the Cell Therapeutics Inc stock, it might explode in near term. Our suggestion will be to make a small position in the stock and wait for little move with higher volumes to make big positions in the stock.
 |
| ARCA Biopharma Inc |
ARCA Biopharma Inc (NASDAQ: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Novartis pursuant to which Novartis is acquiring global patent rights to an undisclosed molecular target. ARCA will receive an upfront payment of $2.0 million and is eligible to receive clinical, regulatory and commercial milestones totaling $17.5 million. Additional terms of the transaction were not disclosed.
ARCA is also currently seeking or evaluating business development opportunities for multiple additional compounds in various stages of development which are outside the Company’s core focus area of cardiovascular disease. These business development efforts do not include ARCA’s lead compound, GencaroTM (bucindolol hydrochloride), which is being developed for cardiovascular disease and for which the Company is seeking strategic partners.To read more, choose from below links
( Business Wire )
 |
| Teva Pharmaceuticals Industries Ltd |
Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) announces second acquisition to Buy Japanese Generic Drugmaker, Taiyo Pharmaceuticals Industry Co. Ltd. for $490 Million.
Globes -- The leading Japanese financial newspaper "Nikkei" reports that Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) is close to acquiring the country's third largest generic drugmaker Taiyo Pharmaceuticals Industry Co. Ltd. for ¥40 billion, which is about $490 million.
This would be the latest in a string of acquisitions by Teva in Japan as the Israeli company strives to increase its activities in the Japanese market.
The reports come on the same day that Teva announced its acquisition of US bio-pharmaceutical company Cephalon (Nasdaq: CEPH) for $6.8 billion, as the Israeli generic giant seeks to expand and diversify its brand drug portfolio, which is highly dependent on sales of multiple sclerosis treatment Copaxone.
( Source: Reuters )
 |
| Bioscrip Inc |
According to a report from an independent rating agency, US debt rated at "C".
From last month there is continuously rising debate over US sovereign rating, after S&P had downgraded AAA rating from stable to negative implying that rating cut could happen in 2 years.
"A 'C' is equivalent to approximately a triple-B on the S&P, Moody's and Fitch scales. It's two notches above junk and one notch above the equivalent of a single A," Martin Weiss, President of Weiss Ratings, told CNBC Tuesday. He also added that although rating seems weak, debt situation is not in a danger zone as there is a strong demand for Treasury.
The U.S. government debt is fast approaching the $14.3 trillion ceiling, with the debt-to-GDP ratio close to 100 percent. And a downgrade of U.S. Treasurys - one of the most widely held assets - could theoretically raise borrowing costs and in a worst case scenario, trigger a default on the government's debt obligations.
America's rating was ranked 33rd out of 47 nations, according to Weiss, which began tracking sovereign debt last year. France and Japan also got a "C" rating, while Only China and Thailand received an "A" rating
See all credit ratings and reports, follow the link below
(Source: CNBC )
 |
| NPS Pharmaceuticals |
(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the first quarter of 2011.
NPS Pharmaceuticals reported a net loss of $9.2 million or $0.13 per diluted share for first quarter of 2011 compared with a net loss of $3.1 million or 0.06 per diluted share a year earlier. The year-over-year change in the company’s financial results were principally driven by the advancement of the company’s two Phase 3 registration programs, GATTEX® (teduglutide) in short bowel syndrome (SBS) and NPSP558 in hypoparathyroidism. On a pro forma basis, cash and investments totaled $220.0 million at March 31, 2011 after including net proceeds of approximately $106.8 million from a recent public offering of common stock.
“The success of our recent equity offering, which raised $107 million, gives us the financial flexibility to deliver a number of key milestones, including the approval of our first product in 2012,” said Francois Nader, M.D., president and chief executive officer of NPS Pharmaceuticals. “We look forward to reporting additional data from the GATTEX Phase 3 clinical program at the upcoming Digestive Disease Week conference in Chicago and submitting the drug for U.S. approval later this year. We also remain on track to report top-line results from the Phase 3 REPLACE study of NPSP558 before year-end.”
 |
| Pfizer Inc |
World's Biggest drug maker Pfizer Inc ( NYSE: PFE ) announced a quarterly results today which were inline with expectations.
Company has earned $2.22 billion, or 28 cents per share, in the first quarter compared with 42.03 billion or 25 cents a share in the year earlier period.
Excluding special items, including its Capsugel business that is being sold and is now considered to be a discontinued operation, Pfizer earned 60 cents per share.Analysts on average expected 59 cents per share, according to Thomson Reuters I/B/E/S.
Global company revenue of $16.5 billion was a bit less of Wall Street expectations of $16.63 billion.
